Health‐related quality‐of‐life scales in Parkinson's disease: Critique and recommendations
Identifieur interne : 000218 ( Main/Curation ); précédent : 000217; suivant : 000219Health‐related quality‐of‐life scales in Parkinson's disease: Critique and recommendations
Auteurs : Pablo Martinez-Martin [Espagne] ; Martine Jeukens-Visser [Pays-Bas] ; Kelly E. Lyons [États-Unis] ; C. Rodriguez-Blazquez [Espagne] ; Caroline Selai [Royaume-Uni] ; Andrew Siderowf [États-Unis] ; Mickie Welsh [États-Unis] ; Werner Poewe [Autriche] ; Oliver Rascol [France] ; Cristina Sampaio [Portugal] ; Glenn T. Stebbins [États-Unis] ; Christopher G. Goetz [États-Unis] ; Anette Schrag [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 2011-11.
English descriptors
- KwdEn :
Abstract
Health‐related quality of life is an important patient‐reported outcome used in intervention trials and for monitoring the consequences of health status on physical, mental, and social domains. Parkinson's disease is a complex disorder that strongly affects patients' quality of life. Several health‐related quality of life tools have been used in Parkinson's disease. A Movement Disorder Society Task Force was commissioned to rate the psychometric quality of available health‐related quality of life scales as applied to Parkinson's disease. Following the methodology adopted by previous work of the Movement Disorder Society Task Force, a review of generic and specific health‐related quality of life scales applied in studies on Parkinson's disease was completed. Considering the scales from 3 perspectives—use in Parkinson's disease, use by multiple research groups, and clinimetric properties—a final classification as “recommended,” “suggested,” or “listed” was applied to each reviewed instrument. Four generic scales (EuroQoL, Nottingham Health Profile, 36‐Item Short‐Form Health Survey, and Sickness Impact Profile) and 5 specific scales (39‐Item Parkinson's Disease Questionnaire, Parkinson's Disease Questionnaire Short Form, Parkinson's Disease Quality of Life Questionnaire, Parkinson's Impact Scale, and Scales for Outcomes in Parkinson's Disease–Psychosocial) reached the level of “recommended.” The 39‐item Parkinson's Disease Questionnaire is the most thoroughly tested and applied questionnaire. Three other generic measures (Quality of Life Questionnaire 15D, Schedule for the Evaluation of Individual Quality of Life‐Direct Weighting, and World Health Organization Quality of Life Assessment Short Version) and the specific Parkinson's Disease Quality of Life Scale are “suggested.” With a little additional effort in completing the stipulated requirements, they could reach the “recommended” level. At present there is a wide variety of health‐related quality of life measures for application in the Parkinson's disease setting, and the task force does not recommend the development of a new scale. Selection of the most appropriate instrument for a particular objective requires consideration of the characteristics of each scale and the goals of the assessment. © 2011 Movement Disorder Society
Url:
DOI: 10.1002/mds.23834
Links toward previous steps (curation, corpus...)
- to stream Main, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000264
Links to Exploration step
ISTEX:C01E2DAFFA05A560AE15850ABA73BB5C7BBF6942Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Health‐related quality‐of‐life scales in Parkinson's disease: Critique and recommendations</title><author><name sortKey="Martinez Artin, Pablo" sort="Martinez Artin, Pablo" uniqKey="Martinez Artin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name><affiliation wicri:level="1"><mods:affiliation>Alzheimer Disease Research Unit, CIEN Foundation–Reina Sofia Foundation, Alzheimer Center Reina Sofia Foundation, Carlos III Institute of Health, Madrid, Spain</mods:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Alzheimer Disease Research Unit, CIEN Foundation–Reina Sofia Foundation, Alzheimer Center Reina Sofia Foundation, Carlos III Institute of Health, Madrid</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>National Center of Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain</mods:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>National Center of Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid</wicri:regionArea></affiliation></author><author><name sortKey="Jeukens Isser, Martine" sort="Jeukens Isser, Martine" uniqKey="Jeukens Isser M" first="Martine" last="Jeukens-Visser">Martine Jeukens-Visser</name><affiliation wicri:level="1"><mods:affiliation>Department of Rehabilitation, Academic Medical Center, Amsterdam, The Netherlands</mods:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Rehabilitation, Academic Medical Center, Amsterdam</wicri:regionArea></affiliation></author><author><name sortKey="Lyons, Kelly E" sort="Lyons, Kelly E" uniqKey="Lyons K" first="Kelly E." last="Lyons">Kelly E. Lyons</name><affiliation wicri:level="1"><mods:affiliation>University of Kansas Medical Center, Parkinson's Disease and Movement Disorder Center, Kansas City, Kansas, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Kansas Medical Center, Parkinson's Disease and Movement Disorder Center, Kansas City, Kansas</wicri:regionArea></affiliation></author><author><name sortKey="Rodriguez Lazquez, C" sort="Rodriguez Lazquez, C" uniqKey="Rodriguez Lazquez C" first="C." last="Rodriguez-Blazquez">C. Rodriguez-Blazquez</name><affiliation wicri:level="1"><mods:affiliation>National Center of Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain</mods:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>National Center of Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid</wicri:regionArea></affiliation></author><author><name sortKey="Selai, Caroline" sort="Selai, Caroline" uniqKey="Selai C" first="Caroline" last="Selai">Caroline Selai</name><affiliation wicri:level="1"><mods:affiliation>Sobell Department of Motor Neuroscience & Movement Disorders, University College London, Institute of Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Sobell Department of Motor Neuroscience & Movement Disorders, University College London, Institute of Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London</wicri:regionArea></affiliation></author><author><name sortKey="Siderowf, Andrew" sort="Siderowf, Andrew" uniqKey="Siderowf A" first="Andrew" last="Siderowf">Andrew Siderowf</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania</wicri:regionArea></affiliation></author><author><name sortKey="Welsh, Mickie" sort="Welsh, Mickie" uniqKey="Welsh M" first="Mickie" last="Welsh">Mickie Welsh</name><affiliation wicri:level="1"><mods:affiliation>Division of Movement Disorders, USC/Keck School of Medicine, University of Southern California, Los Angeles, California, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Movement Disorders, USC/Keck School of Medicine, University of Southern California, Los Angeles, California</wicri:regionArea></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University Hospital, Innsbruck, Austria</mods:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Neurology, University Hospital, Innsbruck</wicri:regionArea></affiliation></author><author><name sortKey="Rascol, Oliver" sort="Rascol, Oliver" uniqKey="Rascol O" first="Oliver" last="Rascol">Oliver Rascol</name><affiliation wicri:level="1"><mods:affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Toulouse, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire de Pharmacologie Medicale et Clinique, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name><affiliation wicri:level="1"><mods:affiliation>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine, Lisbon, Portugal</mods:affiliation><country xml:lang="fr">Portugal</country><wicri:regionArea>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine, Lisbon</wicri:regionArea></affiliation></author><author><name sortKey="Stebbins, Glenn T" sort="Stebbins, Glenn T" uniqKey="Stebbins G" first="Glenn T." last="Stebbins">Glenn T. Stebbins</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurological Services, Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurological Services, Rush University Medical Center, Chicago, Illinois</wicri:regionArea></affiliation></author><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurological Services, Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurological Services, Rush University Medical Center, Chicago, Illinois</wicri:regionArea></affiliation></author><author><name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name><affiliation wicri:level="1"><mods:affiliation>Department of Clinical Neurosciences, Royal Free Hospital, University College London, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Clinical Neurosciences, Royal Free Hospital, University College London, London</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:C01E2DAFFA05A560AE15850ABA73BB5C7BBF6942</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1002/mds.23834</idno><idno type="url">https://api.istex.fr/document/C01E2DAFFA05A560AE15850ABA73BB5C7BBF6942/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000264</idno><idno type="wicri:Area/Main/Curation">000218</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Health‐related quality‐of‐life scales in Parkinson's disease: Critique and recommendations</title><author><name sortKey="Martinez Artin, Pablo" sort="Martinez Artin, Pablo" uniqKey="Martinez Artin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name><affiliation wicri:level="1"><mods:affiliation>Alzheimer Disease Research Unit, CIEN Foundation–Reina Sofia Foundation, Alzheimer Center Reina Sofia Foundation, Carlos III Institute of Health, Madrid, Spain</mods:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Alzheimer Disease Research Unit, CIEN Foundation–Reina Sofia Foundation, Alzheimer Center Reina Sofia Foundation, Carlos III Institute of Health, Madrid</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>National Center of Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain</mods:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>National Center of Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid</wicri:regionArea></affiliation></author><author><name sortKey="Jeukens Isser, Martine" sort="Jeukens Isser, Martine" uniqKey="Jeukens Isser M" first="Martine" last="Jeukens-Visser">Martine Jeukens-Visser</name><affiliation wicri:level="1"><mods:affiliation>Department of Rehabilitation, Academic Medical Center, Amsterdam, The Netherlands</mods:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Rehabilitation, Academic Medical Center, Amsterdam</wicri:regionArea></affiliation></author><author><name sortKey="Lyons, Kelly E" sort="Lyons, Kelly E" uniqKey="Lyons K" first="Kelly E." last="Lyons">Kelly E. Lyons</name><affiliation wicri:level="1"><mods:affiliation>University of Kansas Medical Center, Parkinson's Disease and Movement Disorder Center, Kansas City, Kansas, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Kansas Medical Center, Parkinson's Disease and Movement Disorder Center, Kansas City, Kansas</wicri:regionArea></affiliation></author><author><name sortKey="Rodriguez Lazquez, C" sort="Rodriguez Lazquez, C" uniqKey="Rodriguez Lazquez C" first="C." last="Rodriguez-Blazquez">C. Rodriguez-Blazquez</name><affiliation wicri:level="1"><mods:affiliation>National Center of Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain</mods:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>National Center of Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid</wicri:regionArea></affiliation></author><author><name sortKey="Selai, Caroline" sort="Selai, Caroline" uniqKey="Selai C" first="Caroline" last="Selai">Caroline Selai</name><affiliation wicri:level="1"><mods:affiliation>Sobell Department of Motor Neuroscience & Movement Disorders, University College London, Institute of Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Sobell Department of Motor Neuroscience & Movement Disorders, University College London, Institute of Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London</wicri:regionArea></affiliation></author><author><name sortKey="Siderowf, Andrew" sort="Siderowf, Andrew" uniqKey="Siderowf A" first="Andrew" last="Siderowf">Andrew Siderowf</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania</wicri:regionArea></affiliation></author><author><name sortKey="Welsh, Mickie" sort="Welsh, Mickie" uniqKey="Welsh M" first="Mickie" last="Welsh">Mickie Welsh</name><affiliation wicri:level="1"><mods:affiliation>Division of Movement Disorders, USC/Keck School of Medicine, University of Southern California, Los Angeles, California, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Movement Disorders, USC/Keck School of Medicine, University of Southern California, Los Angeles, California</wicri:regionArea></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University Hospital, Innsbruck, Austria</mods:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Neurology, University Hospital, Innsbruck</wicri:regionArea></affiliation></author><author><name sortKey="Rascol, Oliver" sort="Rascol, Oliver" uniqKey="Rascol O" first="Oliver" last="Rascol">Oliver Rascol</name><affiliation wicri:level="1"><mods:affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Toulouse, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire de Pharmacologie Medicale et Clinique, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name><affiliation wicri:level="1"><mods:affiliation>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine, Lisbon, Portugal</mods:affiliation><country xml:lang="fr">Portugal</country><wicri:regionArea>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine, Lisbon</wicri:regionArea></affiliation></author><author><name sortKey="Stebbins, Glenn T" sort="Stebbins, Glenn T" uniqKey="Stebbins G" first="Glenn T." last="Stebbins">Glenn T. Stebbins</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurological Services, Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurological Services, Rush University Medical Center, Chicago, Illinois</wicri:regionArea></affiliation></author><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurological Services, Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurological Services, Rush University Medical Center, Chicago, Illinois</wicri:regionArea></affiliation></author><author><name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name><affiliation wicri:level="1"><mods:affiliation>Department of Clinical Neurosciences, Royal Free Hospital, University College London, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Clinical Neurosciences, Royal Free Hospital, University College London, London</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-11">2011-11</date><biblScope unit="volume">26</biblScope><biblScope unit="issue">13</biblScope><biblScope unit="page" from="2371">2371</biblScope><biblScope unit="page" to="2380">2380</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">C01E2DAFFA05A560AE15850ABA73BB5C7BBF6942</idno><idno type="DOI">10.1002/mds.23834</idno><idno type="ArticleID">MDS23834</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>assessment</term><term>health‐related quality of life</term><term>measures</term><term>patient‐reported outcomes</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Health‐related quality of life is an important patient‐reported outcome used in intervention trials and for monitoring the consequences of health status on physical, mental, and social domains. Parkinson's disease is a complex disorder that strongly affects patients' quality of life. Several health‐related quality of life tools have been used in Parkinson's disease. A Movement Disorder Society Task Force was commissioned to rate the psychometric quality of available health‐related quality of life scales as applied to Parkinson's disease. Following the methodology adopted by previous work of the Movement Disorder Society Task Force, a review of generic and specific health‐related quality of life scales applied in studies on Parkinson's disease was completed. Considering the scales from 3 perspectives—use in Parkinson's disease, use by multiple research groups, and clinimetric properties—a final classification as “recommended,” “suggested,” or “listed” was applied to each reviewed instrument. Four generic scales (EuroQoL, Nottingham Health Profile, 36‐Item Short‐Form Health Survey, and Sickness Impact Profile) and 5 specific scales (39‐Item Parkinson's Disease Questionnaire, Parkinson's Disease Questionnaire Short Form, Parkinson's Disease Quality of Life Questionnaire, Parkinson's Impact Scale, and Scales for Outcomes in Parkinson's Disease–Psychosocial) reached the level of “recommended.” The 39‐item Parkinson's Disease Questionnaire is the most thoroughly tested and applied questionnaire. Three other generic measures (Quality of Life Questionnaire 15D, Schedule for the Evaluation of Individual Quality of Life‐Direct Weighting, and World Health Organization Quality of Life Assessment Short Version) and the specific Parkinson's Disease Quality of Life Scale are “suggested.” With a little additional effort in completing the stipulated requirements, they could reach the “recommended” level. At present there is a wide variety of health‐related quality of life measures for application in the Parkinson's disease setting, and the task force does not recommend the development of a new scale. Selection of the most appropriate instrument for a particular objective requires consideration of the characteristics of each scale and the goals of the assessment. © 2011 Movement Disorder Society</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000218 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 000218 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Curation
|type= RBID
|clé= ISTEX:C01E2DAFFA05A560AE15850ABA73BB5C7BBF6942
|texte= Health‐related quality‐of‐life scales in Parkinson's disease: Critique and recommendations
}}
| This area was generated with Dilib version V0.6.23. |  |